Aarvik Therapeutics has secured a successful Series Seed 2 financing round. This funding will help advance the company's proprietary MUTTA™ platform and reach targeted research milestones.
Aarvik Therapeutics has successfully closed a Series Seed 2 financing round with a diverse set of investors. The funding validates Aarvik's substantial progress on its MUTTA™ platform. It will enable the company to further advance its pipeline of ADC assets. The new round follows its previous Series Seed financing.
Company Information
Company
Aarvik Therapeutics
Location
Hayward, California, United States
About
Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.
Fundz sees it the moment Aarvik Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
HaywardBiotechnologyHealthcareHealth CareTherapeuticsresearch